Organogenesis Shares Surge After FDA Meeting on ReNu Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ORGO?
Source: stocktwits
- Stock Surge: Organogenesis Holdings Inc. (ORGO) shares rose 7% in after-hours trading on Monday, reflecting market optimism following the company's productive meeting with the U.S. FDA.
- FDA Meeting Outcome: The company plans to initiate a rolling application for its experimental treatment ReNu by the end of December, marking a significant step forward in addressing knee osteoarthritis pain.
- Market Potential: Knee osteoarthritis is a degenerative joint disease affecting nearly 31.1 million Americans, and ReNu, a cryopreserved amniotic suspension allograft, offers anti-inflammatory, growth factor, and cellular components, indicating substantial market demand.
- Non-Surgical Alternative: ReNu provides a non-surgical treatment option aimed at reducing inflammation, alleviating pain, and enhancing joint function, potentially transforming patient treatment choices and strengthening the company's competitive position in the healthcare market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORGO
Wall Street analysts forecast ORGO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.240
Low
9.00
Averages
9.00
High
9.00
Current: 2.240
Low
9.00
Averages
9.00
High
9.00
About ORGO
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Organogenesis to Report Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Organogenesis Holdings Inc. will report its Q1 2026 financial results after market close on May 7, 2026, which is expected to provide investors with critical financial data and business updates to assess the company's operational performance.
- Conference Call Details: Management will host a conference call at 5:00 p.m. Eastern Time on May 7 to discuss quarterly results and conduct a Q&A session, aiming to enhance interaction with investors and improve transparency and trust.
- Webcast Access: Investors can access the live webcast of the conference call through the company’s website or direct links, with the session archived for approximately one year, ensuring that those unable to participate live can still obtain relevant information, thereby enhancing information accessibility.
- Company Overview: Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development and commercialization of advanced wound care and surgical and sports medicine solutions, offering a comprehensive portfolio of innovative regenerative products to meet patient needs, showcasing its leadership in the industry.
See More
Organogenesis Completes PuraPly®AM Clinical Trial with Significant Results
- Clinical Trial Success: Organogenesis's randomized controlled trial involving 170 patients demonstrated that PuraPly®AM combined with standard of care achieved statistically significant wound closure at 12 weeks (p<0.0477), further validating its clinical efficacy in managing non-healing diabetic foot ulcers.
- Future Coverage Policy Support: The publication of these trial results is expected to strongly support the inclusion of PuraPly®AM in future insurance coverage policies, emphasizing its critical role in the healing process and potentially reducing the healthcare burden on patients.
- Product Differentiation Advantage: PuraPly®AM uniquely combines a native cross-linked collagen matrix with the antimicrobial agent PHMB, effectively managing bioburden within the product and supporting healing, showcasing its distinctiveness among skin substitutes.
- Market Potential Outlook: With the growing body of clinical evidence, Organogenesis is poised to achieve significant revenue growth through PuraPly®AM, particularly in light of updated insurance policies, thereby further solidifying its market position in the regenerative medicine sector.
See More
Organogenesis Shares Surge After FDA Meeting on ReNu Approval
- Stock Surge: Organogenesis Holdings Inc. (ORGO) shares rose 7% in after-hours trading on Monday, reflecting market optimism following the company's productive meeting with the U.S. FDA.
- FDA Meeting Outcome: The company plans to initiate a rolling application for its experimental treatment ReNu by the end of December, marking a significant step forward in addressing knee osteoarthritis pain.
- Market Potential: Knee osteoarthritis is a degenerative joint disease affecting nearly 31.1 million Americans, and ReNu, a cryopreserved amniotic suspension allograft, offers anti-inflammatory, growth factor, and cellular components, indicating substantial market demand.
- Non-Surgical Alternative: ReNu provides a non-surgical treatment option aimed at reducing inflammation, alleviating pain, and enhancing joint function, potentially transforming patient treatment choices and strengthening the company's competitive position in the healthcare market.
See More
Organogenesis Completes FDA Meeting, Plans BLA Submission
- Successful FDA Meeting: Organogenesis confirmed the appropriateness of the ReNu clinical development program during a Type-B meeting with the FDA, planning to submit a rolling Biologics License Application (BLA) by the end of 2025, marking a significant advancement in regenerative medicine.
- Large-Scale Clinical Trials: The ReNu clinical development includes two large Phase 3 randomized controlled trials involving over 1,300 patients, demonstrating its potential in treating knee osteoarthritis, and if approved, it will address the growing patient demand.
- Significant Market Need: Knee osteoarthritis affects approximately 31.1 million Americans, projected to rise to 34.4 million by 2027, and the introduction of ReNu will provide new treatment options for this large patient population, improving their quality of life.
- Product Background: ReNu is a cryopreserved amniotic suspension allograft containing cellular, growth factor, and extracellular matrix components, previously marketed under Section 361 of the Public Health Service Act for about six years, showcasing a strong commercial history.
See More
Organogenesis Reports Record Q4 2025 Earnings Amid Market Uncertainty
- Record Sales: Organogenesis achieved net product revenue of $225.1 million in Q4 2025, representing a 78% year-over-year increase and exceeding expectations by $50 million, primarily driven by an 83% growth in Advanced Wound Care product sales, reflecting strong market demand and effective customer relationships.
- Gross Margin Improvement: The gross profit for Q4 was $175.2 million, or 78% of net product revenue, up from 75% last year, indicating success in cost control and pricing strategies, despite operating expenses rising 39% year-over-year.
- 2026 Outlook: The CFO projected a 25% to 38% decline in total net revenue for 2026, primarily due to clinical confusion stemming from CMS policy changes, with first-quarter revenue expected to drop approximately 50%, although the company remains optimistic about market share growth in the second half of the year.
- Strategic Investments: The CEO highlighted investments in a new manufacturing and R&D center in Rhode Island, along with the launch of Dermagraft and expansion plans for FortiShield and TransCyte, demonstrating the company's commitment to long-term growth and entry into new markets.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Organogenesis Holdings
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud against Organogenesis Holdings Inc., suggesting that the company and its executives may have engaged in unlawful business practices, prompting investors to reach out for more information.
- Impact of Healthcare Policy: On December 26, 2025, the Centers for Medicare & Medicaid Services announced the withdrawal of final Local Coverage Determinations related to skin substitute grafts, leading to increased competition from over 300 market participants for Organogenesis.
- Stock Price Decline: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a renowned firm in corporate and securities class litigation, having fought for the rights of victims of securities fraud for over 85 years, highlighting its expertise and influence in such cases.
See More
Organogenesis to Report Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Organogenesis Holdings Inc. will report its Q1 2026 financial results after market close on May 7, 2026, which is expected to provide investors with critical financial data and business updates to assess the company's operational performance.
- Conference Call Details: Management will host a conference call at 5:00 p.m. Eastern Time on May 7 to discuss quarterly results and conduct a Q&A session, aiming to enhance interaction with investors and improve transparency and trust.
- Webcast Access: Investors can access the live webcast of the conference call through the company’s website or direct links, with the session archived for approximately one year, ensuring that those unable to participate live can still obtain relevant information, thereby enhancing information accessibility.
- Company Overview: Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development and commercialization of advanced wound care and surgical and sports medicine solutions, offering a comprehensive portfolio of innovative regenerative products to meet patient needs, showcasing its leadership in the industry.
See More
Organogenesis Completes PuraPly®AM Clinical Trial with Significant Results
- Clinical Trial Success: Organogenesis's randomized controlled trial involving 170 patients demonstrated that PuraPly®AM combined with standard of care achieved statistically significant wound closure at 12 weeks (p<0.0477), further validating its clinical efficacy in managing non-healing diabetic foot ulcers.
- Future Coverage Policy Support: The publication of these trial results is expected to strongly support the inclusion of PuraPly®AM in future insurance coverage policies, emphasizing its critical role in the healing process and potentially reducing the healthcare burden on patients.
- Product Differentiation Advantage: PuraPly®AM uniquely combines a native cross-linked collagen matrix with the antimicrobial agent PHMB, effectively managing bioburden within the product and supporting healing, showcasing its distinctiveness among skin substitutes.
- Market Potential Outlook: With the growing body of clinical evidence, Organogenesis is poised to achieve significant revenue growth through PuraPly®AM, particularly in light of updated insurance policies, thereby further solidifying its market position in the regenerative medicine sector.
See More
Organogenesis Shares Surge After FDA Meeting on ReNu Approval
- Stock Surge: Organogenesis Holdings Inc. (ORGO) shares rose 7% in after-hours trading on Monday, reflecting market optimism following the company's productive meeting with the U.S. FDA.
- FDA Meeting Outcome: The company plans to initiate a rolling application for its experimental treatment ReNu by the end of December, marking a significant step forward in addressing knee osteoarthritis pain.
- Market Potential: Knee osteoarthritis is a degenerative joint disease affecting nearly 31.1 million Americans, and ReNu, a cryopreserved amniotic suspension allograft, offers anti-inflammatory, growth factor, and cellular components, indicating substantial market demand.
- Non-Surgical Alternative: ReNu provides a non-surgical treatment option aimed at reducing inflammation, alleviating pain, and enhancing joint function, potentially transforming patient treatment choices and strengthening the company's competitive position in the healthcare market.
See More
Organogenesis Completes FDA Meeting, Plans BLA Submission
- Successful FDA Meeting: Organogenesis confirmed the appropriateness of the ReNu clinical development program during a Type-B meeting with the FDA, planning to submit a rolling Biologics License Application (BLA) by the end of 2025, marking a significant advancement in regenerative medicine.
- Large-Scale Clinical Trials: The ReNu clinical development includes two large Phase 3 randomized controlled trials involving over 1,300 patients, demonstrating its potential in treating knee osteoarthritis, and if approved, it will address the growing patient demand.
- Significant Market Need: Knee osteoarthritis affects approximately 31.1 million Americans, projected to rise to 34.4 million by 2027, and the introduction of ReNu will provide new treatment options for this large patient population, improving their quality of life.
- Product Background: ReNu is a cryopreserved amniotic suspension allograft containing cellular, growth factor, and extracellular matrix components, previously marketed under Section 361 of the Public Health Service Act for about six years, showcasing a strong commercial history.
See More
Organogenesis Reports Record Q4 2025 Earnings Amid Market Uncertainty
- Record Sales: Organogenesis achieved net product revenue of $225.1 million in Q4 2025, representing a 78% year-over-year increase and exceeding expectations by $50 million, primarily driven by an 83% growth in Advanced Wound Care product sales, reflecting strong market demand and effective customer relationships.
- Gross Margin Improvement: The gross profit for Q4 was $175.2 million, or 78% of net product revenue, up from 75% last year, indicating success in cost control and pricing strategies, despite operating expenses rising 39% year-over-year.
- 2026 Outlook: The CFO projected a 25% to 38% decline in total net revenue for 2026, primarily due to clinical confusion stemming from CMS policy changes, with first-quarter revenue expected to drop approximately 50%, although the company remains optimistic about market share growth in the second half of the year.
- Strategic Investments: The CEO highlighted investments in a new manufacturing and R&D center in Rhode Island, along with the launch of Dermagraft and expansion plans for FortiShield and TransCyte, demonstrating the company's commitment to long-term growth and entry into new markets.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Organogenesis Holdings
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud against Organogenesis Holdings Inc., suggesting that the company and its executives may have engaged in unlawful business practices, prompting investors to reach out for more information.
- Impact of Healthcare Policy: On December 26, 2025, the Centers for Medicare & Medicaid Services announced the withdrawal of final Local Coverage Determinations related to skin substitute grafts, leading to increased competition from over 300 market participants for Organogenesis.
- Stock Price Decline: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a renowned firm in corporate and securities class litigation, having fought for the rights of victims of securities fraud for over 85 years, highlighting its expertise and influence in such cases.
See More
